← Eichor
Condition: Non Small Cell Lung Cancer Patients Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Non Small Cell Lung Cancer Patients

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · BeBetter Med Inc · NCT06706713ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Phase N/A · 1 location(s) · Fang Wu · NCT05198154Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced
Phase 2 · 7 location(s) · Korea Institute of Oriental Medicine · NCT06249854A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
NA · 1 location(s) · Nantes University Hospital · NCT06481813Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Phase 3 · 1 location(s) · Akeso · NCT06928389Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metas
Phase 1 · 5 location(s) · Kiromic BioPharma Inc. · NCT06069570A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
Phase 1/Phase 2 · 1 location(s) · Wuhan YZY Biopharma Co., Ltd. · NCT05543330Immuno-effect of Tα1 for Stage I NSCLC
NA · 1 location(s) · Yousheng Mao · NCT06598839a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Phase 1 · 37 location(s) · Aurigene Discovery Technologies Limited · NCT05865002Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy
NA · 1 location(s) · Hospital Clinic of Barcelona · NCT05636969Pembrolizumab for Advanced NSCLC and PS 2-3
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05589818A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Xuanzhu Biopharmaceutical Co., Ltd. · NCT04996121Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung C
Phase N/A · 1 location(s) · University Of Perugia · NCT07288632HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Phase 2 · 1 location(s) · HC Biopharma Inc. · NCT07169552A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07202364A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07103395Standardization of a Platform of Preclinical Models Derived From NSCLC Patients
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT07629375A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · 419 location(s) · Eli Lilly and Company · NCT06119581Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/Phase 2 · 93 location(s) · Revolution Medicines, Inc. · NCT06162221Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
Phase 2 · 2 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT03803787PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NA · 1 location(s) · University of Washington · NCT04151940Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec
Phase 4 · 33 location(s) · AstraZeneca · NCT07279935Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT06970639A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Phase N/A · 1 location(s) · AIO-Studien-gGmbH · NCT02622581Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03872661
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.